Israeli AI start-up Pepticom receives $5m. in Series A funding - HEALTH & SCIENCE - Jerusalem Post

Jerusalem-based drug discovery start-up Pepticom announced Thursday that it had managed to secure $5 million in Series A funding from the Chartered Group investment firm. The start-up, which was founded in 2011 after it spun out of Yissum, the Hebrew University of Jerusalem's technology transfer company, utilizes advanced AI technology to discover new peptide-based drug candidates and alleviate development risks by searching an enormous set of possible solutions. This streamlined and less risky process has turned them into world leader in the field of peptide drug discovery.